Tuesday, October 13, 2026

Less Than One Hour Before The Market Open, Sypris Solutions Is Down By 4%

Less Than One Hour Before The Market Open, Sypris Solutions Is Down By 4%

(VIANEWS) - The NASDAQ opens in less than one hour and Sypris Solutions's pre-market value is already 4.78% down.

Sypris Solutions's last close was $2.09, 23.16% below its 52-week high of $2.72.

The last session, NASDAQ ended with Sypris Solutions (SYPR) jumping 0.48% to $2.09. NASDAQ slid 1.07% to $11,996.86, after three consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session.

About Sypris Solutions

Sypris Solutions, Inc. provides truck components, oil and gas pipeline components, and aerospace and defense electronics primarily in North America and Mexico. It operates in two segments, Sypris Technologies and Sypris Electronics. The Sypris Technologies segment supplies forged, machined, welded, and heat-treated steel components for the commercial vehicle, off highway vehicle, recreational vehicle, automotive, industrial, light truck, and energy markets. This segment also offers drive train components, including axle shafts, transmission shafts, gear sets, steer axle knuckles, and other components for automotive, truck, and recreational vehicle manufacturers. In addition, it provides value added operations for drive train assemblies; and manufactures pressure closures and other fabricated products for oil and gas pipelines. The Sypris Electronics segment offers electronic manufacturing services, such as circuit card and full box build manufacturing, high reliability manufacturing, systems assembly and integration, design for manufacturability, and design for specification work for aerospace and defense electronics markets. This segment also provides circuit card assembly services for electronic sensors and systems, including radar systems, tactical ground stations, navigation systems, weapons systems, and targeting and warning systems; and value-added solutions, such as low-volume prototype assembly and high-volume turnkey manufacturing. The company also offers engineering design and repair or inspection services. In addition, it sells its engineered product under the Tube Turns brand. The company was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Earnings Per Share

As for profitability, Sypris Solutions has a trailing twelve months EPS of $0.079.

PE Ratio

Sypris Solutions has a trailing twelve months price to earnings ratio of 26.46. Meaning, the purchaser of the share is investing $26.46 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -12.82%.

Sales Growth

Sypris Solutions's sales growth is 5.8% for the ongoing quarter and negative 20% for the next.

Yearly Top and Bottom Value

Sypris Solutions's stock is valued at $2.09 at 09:07 EST, way below its 52-week high of $2.72 and way higher than its 52-week low of $1.71.

More news about Sypris Solutions (SYPR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com